阿斯利康Etcamah数据显示数小时后Olema下降

2026-09-12 06:32

Olema Pharmaceuticals (OLMA), which is developing the estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) palazestrant, is down ~15% in after-hours trading Friday after AstraZeneca (AZN) disclosed the failure of its own SERD and CERAN, Etcamah (camizestrant), as a first-line breast cancer treatment.
Palazestrant is in phase 3 development in a collaboration with Novartis (NVS) as a first-line treatment in combination with the CDK 4/6 inhibitor Kisqali (ribociclib) for metastatic breast cancer.
It is also in phase 3 as a second- and third-line monotherapy.

More on Olema Pharmaceuticals